Great news.
Added with the propriety formulation of Presendin and Orphan Drug Designation, the IP protection is formidable and befitting of a quality biotech.
It appears the EU patent was granted only for ICP related to IIH whereas the US office was more flexible in allowing conditions related raised ICP including TBI, Hydrocephalus etc.
Doesn’t seem to matter though. Once Invex takes Presendin to market for IIH, it’ll be bought out by Big Pharma before they expand to other large scale trials in other indications.
Ann: Invex Granted Key European Patent for Exenatide, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41290 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 59180 | 2 |
View Market Depth
| Last trade - 16.21pm 11/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable